RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. Vendors in the market are spending on R&D for the development of advanced drugs for the treatment of RA. For instance, Arthritis Foundation’s Research Program in RA focuses on discovering and developing tools that will allow physicians to apply personalized treatment plans for individuals with RA. The goals of this program include determination of the drugs that are most effective for specific patients based on progression, and genetics; and development of strategies and treatments that are expected to inhibit the long-term effects of the disease. Analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Complete report of 94 Pages is available @ http://www.reportsnreports.com/reports/292215-global-rheumatoid-arthritis-drugs-market-2014-2018.html.

1. Global Rheumatoid Arthritis Drugs Market 2014-2018
Published: July 2014
Single User PDF: US$ 2500
Corporate User PDF: US$ 3500
Order this report by calling
+1 888 391 5441 or Send an email
to sales@reportsandreports.com
with your contact details and
questions if any.
1© ReportsnReports.com / Contact sales@reportsandreports.com

2. Global Rheumatoid Arthritis Drugs Market 2014-2018
RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists,
fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the
joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints
coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can
occur at any age, even in children, which is called juvenile arthritis. The disease is three times more
common in women than in men. Genetic and environmental elements are known to contribute in the
development of RA.
Vendors in the market are spending on R&D for the development of advanced drugs for the
treatment of RA. For instance, Arthritis Foundation’s Research Program in RA focuses on discovering
and developing tools that will allow physicians to apply personalized treatment plans for individuals
with RA. The goals of this program include determination of the drugs that are most effective for
specific patients based on progression, and genetics; and development of strategies and treatments
that are expected to inhibit the long-term effects of the disease.Analysts forecast the Global
Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018.
Complete report of 94 Pages is available @ http://www.reportsnreports.com/reports/292215-
global-rheumatoid-arthritis-drugs-market-2014-2018.html.
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
2© ReportsnReports.com / Contact sales@reportsandreports.com

3. Global Rheumatoid Arthritis Drugs Market 2014-2018
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Rheumatoid Arthritis
Drugs market for the period 2014-2018. To calculate the market size, the report considers the
revenue generated from the sales of various drugs used in the treatment of RA that are available in
the market. The Global Rheumatoid Arthritis Drugs market can be divided into two segments:
Symptomatic and DMARDs.
Following companies as the key players : AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Co., F.
Hoffmann-La Roche Ltd., Janssen Pharmaceuticals Inc., Pfizer Inc. , AB Science SA, Astellas Pharma
Inc., AstraZeneca plc, Biogen Idec Inc., Boehringer Ingelheim GmbH, Celgene Corp., Daiichi Sankyo
Co. Ltd., Eli Lilly & Co., GE Healthcare Co., Genmab A/S, GSK plc, Incyte Corp., Merck & Co. Inc.,
Mitsubishi Tanabe Pharma Corp., Novartis AG, Novo Nordisk A/S, Rigel Pharmaceuticals Inc., Sanofi,
Takeda Pharmaceutical Co. Ltd., UCB SA, Vertex Pharmaceuticals Inc.
Global Rheumatoid Arthritis Drugs Market 2014-2018, has been prepared based on an in-depth
market analysis with inputs from industry experts. The report covers the Americas and the EMEA and
APAC regions; it also covers the Global Rheumatoid Arthritis Drugs market landscape and its growth
prospects in the coming years. The report also includes a discussion of the key vendors operating in
this market.
Order a copy of this report at @ http://www.reportsnreports.com/Purchase.aspx?name=292215.
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
3© ReportsnReports.com / Contact sales@reportsandreports.com

4. Global Rheumatoid Arthritis Drugs Market 2014-2018
According to the report, the Global RA Drugs market is driven by several factors. One of the main
drivers in this market is the increasing global aging population. The number of patients suffering from
RA is increasing owing to the rising aging population both in developing and developed countries. As
a person ages, the incidence of joint-related disorders such as RA also increases, resulting in the
demand for RA drugs.
Key Regions
Americas, EMEA, APAC
Key Market Driver
Increasing Aging Population
Key Market Challenge
High Cost of RA Treatment
Key Market Trend
Increase in R&D Activities
Inquiry Before Buying on this Report @
http://www.reportsnreports.com/contacts/InquiryBeforeBuy.aspx?name=292215.
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
4© ReportsnReports.com / Contact sales@reportsandreports.com

5. Global Rheumatoid Arthritis Drugs Market 2014-2018
Further, the report states that although the market has several drivers, the Global RA Drugs market is
inhibited by some serious challenges. One of the main challenges is the high cost of RA treatment.
Despite the numerous benefits, the high cost of treatment options hinders the acceptability among
patients.
Key Questions Answered in this Report
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors
Inquire for Discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=292215.
Browse more report on Pharmaceuticals Market
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
5© ReportsnReports.com / Contact sales@reportsandreports.com